RIF-a-MYE-sin

Therapeutic Classification: anti-infectives

Pharmacologic Classification: rifamycins

• Travelers' diarrhea due to noninvasive strains of Escherichia coli.

• Inhibits bacterial synthesis by binding to bacterial DNA-dependent RNA polymerase.

• Decreased severity of travelers' diarrhea.

Spectrum:

• Escherichia coli (enterotoxigenic and enteroaggregative strains).

Absorption: Poorly absorbed (<0.1%), action is primarily in GI tract.

Distribution: Concentrated in gut.

Metabolism/Excretion: Primarily excreted in feces (86%).

Half-life: Unknown.

(plasma concentrations)

Contraindicated in:

• Hypersensitivity to rifamycin or other rifamycins
• Diarrhea with fever or bloody stools
• Diarrhea caused by other infectious agents.

Use Cautiously in:

• OB: Use only if potential maternal benefit justifies potential fetal risk
• Lactation: Use while breastfeeding only if potential maternal benefit justifies potential risk to infant
• Pedi: Safety and effectiveness not established.

GI: CLOSTRIDIUM DIFFICILE-ASSOCIATED DIARRHEA (CDAD), constipation, dyspepsia.

Neuro: headache.

Drug-Drug:

• None reported.

• PO (Adults): 388 mg twice daily for 3 days.

• Delayed-release tablets: 194 mg;

• Consult culture and susceptibility information, if available, and consider local epidemiology and susceptibility patterns in selecting or modifying antibacterial therapy.
• Assess abdomen, bowel sounds, abdominal pain, fever, amount and frequency of diarrhea, and whether stool is bloody. Diarrhea, abdominal cramping, fever, and bloody stools should be reported to health care professional promptly as a sign of Clostridioides difficile-associated diarrhea (CDAD). May begin up to 2 or more months following cessation of therapy.

• PO: Administer 2 tablets twice daily in morning and evening for 3 days. Take each dose with 6–8 oz of water without regard to food. DNC: Swallow tablets whole; do not crush, break, or chew. Avoid alcohol.

• Instruct patient to take rifamycin as directed.
• Advise patient to avoid use of alcohol during therapy.
• Advise patient to discontinue rifamycin if diarrhea persists more than 48 hr or worsens and to seek medical treatment for fever and/or or blood in the stools, and not to treat with antidiarrheals without consulting health care professional.
• Advise females of reproductive potential to notify health care professional if pregnancy is planned or suspected or if breastfeeding.

• Decrease in symptoms of traveler's diarrhea.

Aemcolo

NDC Code^*

• 71068- Aries Pharmaceuticals Inc
  • 71068-001- Aemcolo
    • 71068-001-10- 1 BLISTER PACK in 1 CARTON (71068-001-10) > 12 TABLET, DELAYED RELEASE in 1 BLISTER PACK (71068-001-00)

• 71068- Aries Pharmaceuticals Inc
  • 71068-001- Aemcolo
    • 71068-001-11- 3 BLISTER PACK in 1 CARTON (71068-001-11) > 12 TABLET, DELAYED RELEASE in 1 BLISTER PACK (71068-001-00)

• 71068- Aries Pharmaceuticals Inc
  • 71068-001- Aemcolo
    • 71068-001-98- 1 BLISTER PACK in 1 CARTON (71068-001-98) > 12 TABLET, DELAYED RELEASE in 1 BLISTER PACK (71068-001-88)